financetom
OFIX
financetom
/
Healthcare
/
OFIX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Orthofix Medical Inc.OFIX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Orthofix Medical Inc. operates spine and orthopedics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally.

It operates through Global Spine and Global Orthopedics segments. The Global Spine segment comprises the bone growth therapies products, which manufactures and distributes bone growth stimulator devices for enhance of bone fusion including adjunctive and noninvasive treatment of cervical and lumbar spine as well as a therapeutic treatment for non-spine; the spinal implants products designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and the biological products, such as regenerative products and tissue forms which allow physicians to treat a variety of spinal and orthopedic conditions.

Global Orthopedics segment offers products and solutions that allow physicians to treat a variety of orthopedic conditions unrelated to the spine, which design, develop, and market the orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures.

It sells its products through distributors, sales representatives, hospitals, and healthcare providers.

The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018.

Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.

Latest News >
Merck's Phase 3 Trial of Enlicitide Decanoate in Heterozygous Familial Hypercholesterolemia Achieves Primary Endpoint
Merck's Phase 3 Trial of Enlicitide Decanoate in Heterozygous Familial Hypercholesterolemia Achieves Primary Endpoint
Nov 10, 2025
05:54 AM EST, 11/10/2025 (MT Newswires) -- Merck ( MRK ) said Sunday that a phase 3 study of its elicitide decanoate product candidate achieved its primary endpoint, demonstrating statistically significant reduction in low-density lipoprotein cholesterol, or LDL-C, in adult patients with heterozygous familial hypercholesterolemia. The company said enlicitide led to a clinically meaningful LDL-C reduction of 59.4% compared with...
Cargojet Renews Normal Course Issuer Bid for Voting Shares
Cargojet Renews Normal Course Issuer Bid for Voting Shares
Nov 10, 2025
05:55 AM EST, 11/10/2025 (MT Newswires) -- Cargojet ( CGJTF ) , which rose 2.5% on Friday, later that day said it has received approval from the Toronto Stock Exchange to renew its normal course issuer bid for common voting shares and variable voting shares. The NCIB is scheduled to run from Nov. 11, 2025, to Nov. 10, 2026. Purchases...
Optimism Around US Government Shutdown End, China Inflation Views Lift Asian Stock Markets
Optimism Around US Government Shutdown End, China Inflation Views Lift Asian Stock Markets
Nov 10, 2025
05:38 AM EST, 11/10/2025 (MT Newswires) -- Asian stock markets rose Monday following media reports that the US government shutdown may be nearing an end, and after relatively positive inflation reports from Beijing. Hong Kong, Shanghai and Tokyo finished in the green, as did most other regional exchanges. The South Korean KOSPI rose 3% on the US outlook, and hopes...
Monroe Capital Supports Respida Capital’s Acquisition of ENTOUCH
Monroe Capital Supports Respida Capital’s Acquisition of ENTOUCH
Nov 10, 2025
CHICAGO--(BUSINESS WIRE)-- Monroe Capital LLC (“Monroe”) announced it led the growth capital investment to support the acquisition of ENTOUCH by Respida Capital. Founded in Dallas, Texas in 2008, ENTOUCH provides energy management as a service and smart building technology. The company’s cloud-based software delivers sustainable solutions that reduce energy usage, drive profitably, and simplify facility management for multisite operators. “We...
Copyright 2023-2026 - www.financetom.com All Rights Reserved